Aldose reductase inhibitors pharmacokinetics

This title compound, aldose reductase inhibitor CP-73,850 (zopolrestat) 189, has been 14C-labelled191 (equation 75) for use in metabolism and pharmacokinetic studies, since... 

The lens grows with age, and colorations or opacities may develop and interfere with vision. Cataract formation may be enhanced by some miotics, steroids, and phenothi-azines. Aldose reductase inhibitors, which prevent the conversion of sugars to polyols, appear to prevent or delay diabetic cataract. Levels of glutathione and other compounds drop during the formation of some types of cataracts.The pharmacokinetics of delivery and penetration of such compounds into the crystalline lens is currently of great interest. 

The development of aldose reductase inhibitors as useful drugs is actually at the stage of evaluation of their pharmacodynamic benefit. Data on the pharmacokinetic properties of these drugs are therefore rather scarce. In addition, owing to their chemical heterogeneity, no common principles can be established. 

---